 NRx Pharmaceuticals NASDAQ: NRXP has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Incs NASDAQ: GILD remdesivir in the COVID-AIV trial representing approximately 70 of the study population. The analysis indicates a substantial improvement after Zyesami aviptadil treatment in patients with critical COVID-19 and Respiratory Failure over existing therapies. 